JP2023501276A5 - - Google Patents
Info
- Publication number
- JP2023501276A5 JP2023501276A5 JP2022525603A JP2022525603A JP2023501276A5 JP 2023501276 A5 JP2023501276 A5 JP 2023501276A5 JP 2022525603 A JP2022525603 A JP 2022525603A JP 2022525603 A JP2022525603 A JP 2022525603A JP 2023501276 A5 JP2023501276 A5 JP 2023501276A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hla
- antigen
- bispecific antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207090 | 2019-11-05 | ||
| EP19207090.2 | 2019-11-05 | ||
| PCT/EP2020/080763 WO2021089513A1 (en) | 2019-11-05 | 2020-11-03 | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501276A JP2023501276A (ja) | 2023-01-18 |
| JP2023501276A5 true JP2023501276A5 (https=) | 2023-11-13 |
Family
ID=68468600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525603A Pending JP2023501276A (ja) | 2019-11-05 | 2020-11-03 | Ｈｌａ－ａ２／ｗｔ１×ｃｄ３二重特異性抗体及びレナリドマイドを使用するがんの治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275093A1 (https=) |
| EP (1) | EP4054716A1 (https=) |
| JP (1) | JP2023501276A (https=) |
| KR (1) | KR20220093323A (https=) |
| CN (1) | CN115003384A (https=) |
| AU (1) | AU2020381349A1 (https=) |
| BR (1) | BR112022008652A2 (https=) |
| CA (1) | CA3155308A1 (https=) |
| IL (1) | IL292103A (https=) |
| MX (1) | MX2022005238A (https=) |
| TW (1) | TW202132341A (https=) |
| WO (1) | WO2021089513A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4426735A1 (en) * | 2021-11-01 | 2024-09-11 | F. Hoffmann-La Roche AG | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and a 4-1bb (cd137) agonist |
| WO2024149821A1 (en) * | 2023-01-13 | 2024-07-18 | F. Hoffmann-La Roche Ag | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine |
| CN121909214A (zh) * | 2023-07-31 | 2026-04-21 | 玫帝托克斯股份有限公司 | 一种抗体及包含该抗体的用于治疗免疫疾病的药物组合物 |
| WO2025103425A1 (en) * | 2023-11-15 | 2025-05-22 | Concept To Medicine Biotech Co., Ltd. | Multispecific antibodies and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| WO2018081361A1 (en) * | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Methods and compositions for treatment of myelodyspastic syndromes and/or acute myleoid leukemias |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| MX2020006119A (es) | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
-
2020
- 2020-11-03 MX MX2022005238A patent/MX2022005238A/es unknown
- 2020-11-03 CN CN202080076682.8A patent/CN115003384A/zh active Pending
- 2020-11-03 BR BR112022008652A patent/BR112022008652A2/pt not_active Application Discontinuation
- 2020-11-03 EP EP20797512.9A patent/EP4054716A1/en active Pending
- 2020-11-03 AU AU2020381349A patent/AU2020381349A1/en not_active Abandoned
- 2020-11-03 KR KR1020227015509A patent/KR20220093323A/ko not_active Withdrawn
- 2020-11-03 JP JP2022525603A patent/JP2023501276A/ja active Pending
- 2020-11-03 CA CA3155308A patent/CA3155308A1/en active Pending
- 2020-11-03 WO PCT/EP2020/080763 patent/WO2021089513A1/en not_active Ceased
- 2020-11-04 TW TW109138371A patent/TW202132341A/zh unknown
-
2022
- 2022-04-10 IL IL292103A patent/IL292103A/en unknown
- 2022-05-05 US US17/662,117 patent/US20220275093A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501276A5 (https=) | ||
| JP2022551969A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| JP2021512630A5 (https=) | ||
| JP2023085476A5 (https=) | ||
| JP2024534545A5 (https=) | ||
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021522162A5 (https=) | ||
| JP2021507698A5 (https=) | ||
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP2019533441A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2017537896A5 (https=) | ||
| JP2019502712A5 (https=) | ||
| JP2021521781A5 (https=) | ||
| IL302486A (en) | Antibodies against the transnephrine receptor with adapted affinity | |
| JP2023554500A5 (https=) | ||
| JP2021515793A5 (https=) | ||
| JP2023516195A5 (https=) | ||
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| RU2023135060A (ru) | Антитела, связывающиеся с cd3 | |
| RU2021132277A (ru) | Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv | |
| JP2024543942A5 (https=) | ||
| JP2022028645A5 (https=) |